Sherene Loi

机构：The University of Melbourne, Peter MacCallum Cancer Centre · ORCID：0000-0001-6137-9171

发表论文 1200 篇 · 总被引 82368 次 · h-index 128

代表论文

• Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival (2025 · ESMO Open · 被引 36)
• Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer (2025 · Annals of Oncology · 被引 29)
• Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ ERBB2 -Negative Early Breast Cancer (2025 · JAMA Oncology · 被引 21)
• Parity and lactation induce T-cell-mediated breast cancer protection (2025 · Nature · 被引 17)
• Tucatinib and trastuzumab emtansine for patients with previously treated HER2-positive locally advanced and metastatic breast cancer: primary analysis of the randomized phase III trial HER2CLIMB-02 (2025 · Annals of Oncology · 被引 7)
• The Lucerne Toolbox 3: digital health and artificial intelligence to optimise the patient journey in early breast cancer—a multidisciplinary consensus (2025 · The Lancet Oncology · 被引 4)